Chad F. Phipps Sells 20,826 Shares of Zimmer Biomet Holdings Inc (ZBH) Stock

Zimmer Biomet Holdings Inc (NYSE:ZBH) VP Chad F. Phipps sold 20,826 shares of the firm’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $115.95, for a total value of $2,414,774.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Zimmer Biomet Holdings Inc (ZBH) opened at $119.79 on Friday. The firm has a market capitalization of $24,250.00, a P/E ratio of 13.28, a PEG ratio of 2.04 and a beta of 1.08. Zimmer Biomet Holdings Inc has a 1 year low of $108.03 and a 1 year high of $133.49. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.52 and a quick ratio of 0.83.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Tuesday, January 30th. The medical equipment provider reported $2.10 earnings per share for the quarter, meeting the consensus estimate of $2.10. The business had revenue of $2.07 billion for the quarter, compared to the consensus estimate of $2.03 billion. Zimmer Biomet had a return on equity of 15.45% and a net margin of 23.51%. The business’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the business posted $2.14 earnings per share. sell-side analysts expect that Zimmer Biomet Holdings Inc will post 7.82 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Monday, January 29th. Stockholders of record on Friday, December 29th were given a $0.24 dividend. The ex-dividend date was Thursday, December 28th. This represents a $0.96 annualized dividend and a dividend yield of 0.80%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 10.64%.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Private Advisor Group LLC lifted its position in Zimmer Biomet by 18.6% during the third quarter. Private Advisor Group LLC now owns 6,733 shares of the medical equipment provider’s stock worth $791,000 after buying an additional 1,057 shares in the last quarter. Ingalls & Snyder LLC lifted its position in Zimmer Biomet by 2.6% during the third quarter. Ingalls & Snyder LLC now owns 19,675 shares of the medical equipment provider’s stock worth $2,304,000 after buying an additional 507 shares in the last quarter. Jana Partners LLC lifted its position in Zimmer Biomet by 16.6% during the third quarter. Jana Partners LLC now owns 4,662,497 shares of the medical equipment provider’s stock worth $545,932,000 after buying an additional 662,497 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in Zimmer Biomet by 10.0% during the third quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 16,444 shares of the medical equipment provider’s stock worth $1,925,000 after buying an additional 1,494 shares in the last quarter. Finally, WINTON GROUP Ltd purchased a new position in Zimmer Biomet during the third quarter worth approximately $370,000. Institutional investors and hedge funds own 86.36% of the company’s stock.

Several analysts recently commented on the company. Jefferies Group reaffirmed a “buy” rating and set a $136.00 target price on shares of Zimmer Biomet in a report on Friday, November 3rd. SunTrust Banks raised their target price on Zimmer Biomet to $142.00 and gave the stock a “buy” rating in a report on Monday, January 29th. Stifel Nicolaus reiterated a “hold” rating and set a $120.00 price target on shares of Zimmer Biomet in a research report on Friday, November 3rd. TheStreet downgraded Zimmer Biomet from a “b-” rating to a “c+” rating in a research report on Friday, November 24th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Zimmer Biomet in a research report on Friday, January 5th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. Zimmer Biomet currently has a consensus rating of “Buy” and a consensus price target of $141.67.

TRADEMARK VIOLATION NOTICE: “Chad F. Phipps Sells 20,826 Shares of Zimmer Biomet Holdings Inc (ZBH) Stock” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/16/chad-f-phipps-sells-20826-shares-of-zimmer-biomet-holdings-inc-zbh-stock.html.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply